GlassScriptPhysician profile
Robert C Dobrowolski
NPI 1154406437
$5,884.58
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.99 · 2021: $1,750 · 2022: $2,140 · 2023: $1,827 · 2024: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,954.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $1,050.01 | 2021-2023 | Senza |
| Janssen Pharmaceuticals, INC | $864.94 | 2021-2023 | Xarelto, Spravato |
| Novo Nordisk INC | $679.35 | 2021-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $615.29 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $585.24 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Astrazeneca Pharmaceuticals LP | $507.02 | 2021-2023 | Fasenra |
| Bayer Healthcare Pharmaceuticals INC. | $282.69 | 2021-2022 | |
| Amgen INC. | $249.98 | 2023 | Evenity, Repatha |
| Glaxosmithkline, LLC. | $144.56 | 2021-2023 | Arexvy, Shingrix |
| Althera Pharmaceuticals LLC | $137.86 | 2022 | |
| Edwards Lifesciences Corporation | $124.99 | 2023 | Sapien 3 Ultra Resilia |
| Actelion Pharmaceuticals US, INC. | $124.99 | 2023 | Uptravi, Opsumit |
| Esperion Therapeutics, INC. | $124.94 | 2021 | |
| Intuity Medical INC | $115.74 | 2022 | |
| Pfizer INC. | $45.44 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $45.32 | 2022-2023 | Verquvo, Dificid |
| Otsuka America Pharmaceutical, INC. | $34.24 | 2023 | Nuedexta |
| Abbott Laboratories | $22.73 | 2024 | Freestyle Libre 3 |
| Si-Bone, INC. | $21.09 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.94 | 2021 | |
| Corcept Therapeutics | $20.77 | 2021 | |
| Amarin Pharma, INC. | $18.41 | 2021 | |
| Corium, LLC | $17.97 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.42 | 2022 | |
| Dexcom, INC. | $12.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dobrowolski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.